Humana to Waive Patients’ Share of Some Costs for Rest of 2020
(Bloomberg) -- Health insurer Humana Inc. will waive the costs its Medicare customers are normally expected to pick up for primary care, behavioral health and telehealth visits through the end of the year.
The change will apply to Humana's 4.5 million members in private Medicare Advantage plans, , the company said Tuesday, covering co-pays, co-insurance and deductibles at in-network providers from May 1 through the end of 2020.
Chief Executive Officer Bruce Broussard said in an interview that the change should help members who have deferred care because of the coronavirus pandemic and improve the finances of medical practices hurt by the falloff in patient visits. He didn't give an estimate for how much the change would cost Humana but called it “fully manageable.”
As an intermediary between patients and doctors, insurers have benefited in the short-term from patients staying home. They have continued to collect premiums from employers and government programs even as medical claims dry up.
The services affected include primary care, mental and behavioral health visits for issues like depression that could be exacerbated by the pandemic, the company said.
The move is intended to help members reconnect with clinicians they may not have been able to see while states enforced distancing measures to prevent the spread of Covid-19. Cost-sharing can discourage people from getting care, potentially allowing medical conditions to deteriorate.
“People that are on fixed incomes, we have found they will delay care for financial co-pay reasons,” Broussard said.
Safety Kits
Humana has been reaching out to its most vulnerable members to ensure they get needed services, he said. The company is also sending members “safety kits” that include masks and information on how to seek medical care. It is encouraging members to only resume in-person care in accordance with authorities' guidelines on physical distancing.
Efforts to slow the spread of the virus by closing much face-to-face business have hit the medical industry hard. Canceled office visits and delayed surgeries have strained hospitals, medical practices and other care providers.
Health insurers have seen drops in medical claims since mid-March, and may book higher-than-expected profits in the second quarter as a result. The largest publicly traded insurers, including Humana, have also maintained their profit forecasts for the year. Some insurers said they expect demand for care to recover later in the year.
Many insurers have waived cost-sharing for both testing and treatment of Covid-19 and raised reimbursement rates for telehealth. The industry may come under more pressure from regulators to expand access for patients. Regulators in New York, for example, last week required insurers to cover essential workers' share of the costs for behavioral-health treatments.
©2020 Bloomberg L.P.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.